FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954838067> ?p ?o ?g. }

• W2954838067 endingPage "S133" @default.
• W2954838067 startingPage "S133" @default.
• W2954838067 abstract "The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycemic efficacy is dependent on glomerular filtration. We conducted a systematic review and meta-analysis to assess the effect of SGLT2 inhibitors on a range of biomarkers as well as cardiovascular, renal, and safety outcomes in individuals with T2DM and CKD, defined as an estimated glomerular filtration rate <60 mL/min/1.73m2. We searched MEDLINE, EMBASE and the Cochrane Library to August 8, 2018, as well as the websites of the United States, European, and Japanese regulatory authorities to July 27, 2018 for data from randomized controlled trials of SGLT2 inhibitors that included reporting of effects on biomarkers, cardiovascular, renal, or safety outcomes in individuals with T2DM and CKD. Random effects models and inverse variance weighting were used to calculate relative risks with 95% confidence intervals. Data were obtained from 27 studies with up to 6,590 individuals contributing. The risk of bias in included studies was generally low. Among individuals with T2DM and CKD, SGLT2 inhibitors reduced the risk of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke (RR 0.78, 95% CI 0.65-0.92) and hospitalisation for heart failure (RR 0.58, 95% CI 0.44-0.77). SGLT2 inhibitors attenuated the annual decline in kidney function (annual mean slope difference of 1.35 mL/min/1·73m2/year, 95% CI 0.78-1.93) but there was no clear effect on the composite renal outcome of doubling of serum creatinine, end-stage kidney disease or renal death (RR 0.76, 95% CI 0.54-1.07). There was no evidence of additional risks with SGLT2 inhibition in CKD beyond those already known for the class, although heterogeneity was observed across individual agents for some safety outcomes. In individuals with T2DM and CKD, SGLT2 inhibitors reduced the risk of cardiovascular events and slowed the loss of kidney function, with no evidence of additional safety concerns. Restrictions on the use of SGLT2 inhibitors in this population may warrant review." @default.
• W2954838067 created "2019-07-12" @default.
• W2954838067 creator A5007500444 @default.
• W2954838067 creator A5015488634 @default.
• W2954838067 creator A5027520502 @default.
• W2954838067 creator A5031624913 @default.
• W2954838067 creator A5034930849 @default.
• W2954838067 creator A5038960505 @default.
• W2954838067 creator A5056130529 @default.
• W2954838067 creator A5059943171 @default.
• W2954838067 creator A5075162144 @default.
• W2954838067 creator A5088941984 @default.
• W2954838067 date "2019-07-01" @default.
• W2954838067 modified "2023-10-16" @default.
• W2954838067 title "SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE" @default.
• W2954838067 doi "https://doi.org/10.1016/j.ekir.2019.05.338" @default.
• W2954838067 hasPublicationYear "2019" @default.
• W2954838067 type Work @default.
• W2954838067 sameAs 2954838067 @default.
• W2954838067 citedByCount "0" @default.
• W2954838067 crossrefType "journal-article" @default.
• W2954838067 hasAuthorship W2954838067A5007500444 @default.
• W2954838067 hasAuthorship W2954838067A5015488634 @default.
• W2954838067 hasAuthorship W2954838067A5027520502 @default.
• W2954838067 hasAuthorship W2954838067A5031624913 @default.
• W2954838067 hasAuthorship W2954838067A5034930849 @default.
• W2954838067 hasAuthorship W2954838067A5038960505 @default.
• W2954838067 hasAuthorship W2954838067A5056130529 @default.
• W2954838067 hasAuthorship W2954838067A5059943171 @default.
• W2954838067 hasAuthorship W2954838067A5075162144 @default.
• W2954838067 hasAuthorship W2954838067A5088941984 @default.
• W2954838067 hasBestOaLocation W29548380671 @default.
• W2954838067 hasConcept C126322002 @default.
• W2954838067 hasConcept C127413603 @default.
• W2954838067 hasConcept C134018914 @default.
• W2954838067 hasConcept C159641895 @default.
• W2954838067 hasConcept C177713679 @default.
• W2954838067 hasConcept C207103383 @default.
• W2954838067 hasConcept C2776478404 @default.
• W2954838067 hasConcept C2777180221 @default.
• W2954838067 hasConcept C2778653478 @default.
• W2954838067 hasConcept C2780473172 @default.
• W2954838067 hasConcept C2780645631 @default.
• W2954838067 hasConcept C2910068830 @default.
• W2954838067 hasConcept C44249647 @default.
• W2954838067 hasConcept C500558357 @default.
• W2954838067 hasConcept C555293320 @default.
• W2954838067 hasConcept C71924100 @default.
• W2954838067 hasConcept C78519656 @default.
• W2954838067 hasConcept C82789193 @default.
• W2954838067 hasConcept C95190672 @default.
• W2954838067 hasConceptScore W2954838067C126322002 @default.
• W2954838067 hasConceptScore W2954838067C127413603 @default.
• W2954838067 hasConceptScore W2954838067C134018914 @default.
• W2954838067 hasConceptScore W2954838067C159641895 @default.
• W2954838067 hasConceptScore W2954838067C177713679 @default.
• W2954838067 hasConceptScore W2954838067C207103383 @default.
• W2954838067 hasConceptScore W2954838067C2776478404 @default.
• W2954838067 hasConceptScore W2954838067C2777180221 @default.
• W2954838067 hasConceptScore W2954838067C2778653478 @default.
• W2954838067 hasConceptScore W2954838067C2780473172 @default.
• W2954838067 hasConceptScore W2954838067C2780645631 @default.
• W2954838067 hasConceptScore W2954838067C2910068830 @default.
• W2954838067 hasConceptScore W2954838067C44249647 @default.
• W2954838067 hasConceptScore W2954838067C500558357 @default.
• W2954838067 hasConceptScore W2954838067C555293320 @default.
• W2954838067 hasConceptScore W2954838067C71924100 @default.
• W2954838067 hasConceptScore W2954838067C78519656 @default.
• W2954838067 hasConceptScore W2954838067C82789193 @default.
• W2954838067 hasConceptScore W2954838067C95190672 @default.
• W2954838067 hasIssue "7" @default.
• W2954838067 hasLocation W29548380671 @default.
• W2954838067 hasOpenAccess W2954838067 @default.
• W2954838067 hasPrimaryLocation W29548380671 @default.
• W2954838067 hasRelatedWork W1885119863 @default.
• W2954838067 hasRelatedWork W2217553306 @default.
• W2954838067 hasRelatedWork W2286083054 @default.
• W2954838067 hasRelatedWork W2430940777 @default.
• W2954838067 hasRelatedWork W2768091966 @default.
• W2954838067 hasRelatedWork W2802976988 @default.
• W2954838067 hasRelatedWork W2884289628 @default.
• W2954838067 hasRelatedWork W2889368357 @default.
• W2954838067 hasRelatedWork W2903890959 @default.
• W2954838067 hasRelatedWork W2954318858 @default.
• W2954838067 hasVolume "4" @default.
• W2954838067 isParatext "false" @default.
• W2954838067 isRetracted "false" @default.
• W2954838067 magId "2954838067" @default.
• W2954838067 workType "article" @default.